Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan or HER3-DXd Combinations in Second-Line Advanced Gastroesophageal Adenocarcinoma (Substudy 06D)
NCT06445972Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of sacituzumab tirumotecan and patritumab deruxtecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 60 days and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecanpatritumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT06445972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445972.